| 1. |
166P Insights in the mode of action of a T cell bispecific antibody in tumour bearing mice |
Giusti A, Sam J, Karagianni M, et al. |
|
| 2. |
78P A systematic review and meta-analysis of trials assessing activity of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for pre-treated advanced malignant mesothelioma (aMM) |
Tagliamento M, Bironzo P, De Luca E, et al. |
|
| 3. |
77P The characteristics of long-lasting responders to PD-1 inhibitor in advanced non-small cell lung cancer patients |
Jo H, Yoshida T, Yagishita S, et al. |
|
| 4. |
12P The expression of PD-1 alone by T cells is associated with cell activation while the co-expression of TIM-3 indicates exhausted subsets both in peripheral blood and bone marrow of multiple myeloma patients |
Batorov E, Sergeevicheva V, Aristova T, et al. |
|
| 5. |
151P Investigation of the mechanism of action of anti-PD-1 treatment by systematic depletion of different immune cell populations in syngeneic models |
Bourre L, Jin Y, Muntel J, et al. |
|
| 6. |
6P Prognostic significance of tumour-infiltrating lymphocytes on survival outcomes of patients with resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis |
Tan H, Catedral L, San Juan M. |
|
| 7. |
54P Applicability of the LIPI score to metastatic microsatellite instability high cancer patients treated with immune checkpoint inhibitors |
Vuagnat P, Auclin E, Mezquita L, et al. |
|
| 8. |
LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study |
Herbst R, de Marinis F, Giaccone G, et al. |
|
| 9. |
35O Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer |
Lin Y, Chen S, Zhong S, et al. |
|
| 10. |
161P Regulatory interacting network between the immunomodulatory non-coding RNAs: miR-17-5p, MALAT1 and H19 lncRNAs in modulating the tumour microenvironment in TNBC |
Soliman R, Youness R, El-Shazly M, et al. |
|
| 11. |
47O Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice |
Drakaki A, Luhn P, Wakelee H, et al. |
|
| 12. |
48P A retrospective, observational study of telomerase peptide immunotherapy in heavily treated solid cancer patients |
Choi J. |
|
| 13. |
162TiP A phase I study evaluating BI 765063, a first in class selective myeloid SIRPa inhibitor, as standalone and in combination with BI 754091, a programmed death-1 (PD-1) inhibitor, in patients with advanced solid tumours |
Marabelle A, Cassier P, Delord J, et al. |
|
| 14. |
49P Thromboembolic risk assessment in patients receiving combination of anti-angiogenic plus anti-PD1 or anti-PD-L1: A descriptive study |
Bravo P, Vss B, Baldini C, et al. |
|
| 15. |
135P Analysis of the immune microenvironment in pre-treatment non-small cell lung cancer (NSCLC) patients with follow-up response data to second-line immunotherapy |
Bhagat M, Warren S, Elliott N, et al. |
|
| 16. |
LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis |
Paz-Ares L, Ciuleanu T, Yu X, et al. |
|
| 17. |
7P Multispectral immunofluorescence and computational imaging analysis define the prognostic role of T-cell infiltrates in gastric cancer |
Challoner B, von Loga K, Woolston A, et al. |
|
| 18. |
160P Novel arginase inhibitor alone and in combination with an immune check point inhibitor reduces tumour growth in murine experimental gliomas |
Pilanc-kudlek P, Cyranowski S, Wojnicki K, et al. |
|
| 19. |
116P Development of advanced human immune system mouse models for pre-clinical research in immuno-oncology |
Mossu A, Tschumi B. |
|
| 20. |
130O Association of long non-coding RNA biomarkers with clinically immune subtype and prediction of immunotherapy in patients with cancer |
Yu Y, Zhang W, Li A, et al. |
|
| 21. |
96P Clearance of HPV anal premalignant lesions and modulation of systemic immune responses to HPV oncogenes with low dose pomalidomide |
Polizzotto M, Van Bockel D, Law C, et al. |
|
| 22. |
52P Chronic and late-onset toxicities from immune checkpoints inhibitors (ICIs): Analysis of the publications leading to ICIs approval between 2011 and 2019 |
Ghisoni E, Marandino L, Valabrega G, et al. |
|
| 23. |
123P Patient-Derived Explant Cultures (PDECs) as a model system for immuno-oncology studies |
Turpin R, Munne P, Suleymanova I, et al. |
|
| 24. |
LBA5 KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC |
Gadgeel S, Rodriguez-Abreu D, Felip E, et al. |
|
| 25. |
137P Comparative analysis of the immune microenvironment in histological subtypes of lung and breast cancer using a tissue microarray (TMA) comprising invasive margin (IM) and tumour centre (TC) |
Cumberbatch M, Memeo L, Womack C, et al. |
|
| 26. |
45P 5-AZA treatment induces cytotoxicity and in vitro expression of immunogenic NY-ESO-1 antigen in non-small lung cancer cell NCI-H1975 |
Inchakalody V, Taleb S, Sherif S, et al. |
|
| 27. |
39P TCR engaging antigen-scaffolds for targeted expansion of functionally improved T cells for adoptive cell therapy |
Kladis G, Mindahl V, Tamhane T, et al. |
|
| 28. |
147P A personalised approach for anti-GITR-based immunotherapy in pre-clinical models of pancreatic ductal adenocarcinoma |
Desai K, Ragulan C, Lawrence P, et al. |
|
| 29. |
102P Results from a phase II trial of pembrolizumab (P) plus gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 (PANGEA-Breast) study |
Merino L, Cruz J, Alonso J, et al. |
|
| 30. |
159P Supportive roles of microglia in breast cancer brain metastases |
Kaminska B, Wojnicki K, Kochalska A, et al. |
|
| 31. |
38P Obtaining tumour-specific T cells in a mouse melanoma model |
Yuzhakova D, Izosimova A, Barbashova L, et al. |
|
| 32. |
LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN |
Özgüroğlu M, Goldman J, Reinmuth N, et al. |
|
| 33. |
100P Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer |
Marquez-Rodas I, Longo F, Aix S, et al. |
|
| 34. |
113P A phase I study of an anti-IDO1 inhibitor (LY3381916) as monotherapy and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer |
Kotecki N, O'Neil B, Jalal S, et al. |
|
| 35. |
56P Predictive factors of intensive care outcomes of patients admitted with immune-related adverse events |
Paiva R, Cojocaru E, Grover V. |
|
| 36. |
91O A multi-center phase IIa trial to assess the safety and efficacy of BL-8040 (a CXCR4 inhibitor) in combination with pembrolizumab and chemotherapy in patients with metastatic pancreatic adenocarcinoma (PDAC) |
Hidalgo M, Semenisty V, Bockorny B, et al. |
|
| 37. |
46O Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated |
De Giglio A, Mezquita L, Auclin E, et al. |
|
| 38. |
51P Oncologists’ consideration of health-related quality of life in clinical practice for immune-checkpoint inhibitors-treated patients: An online patients community research |
Wilczynski O, Boisbouvier A, Radoszycki L, et al. |
|
| 39. |
20P The immune profiles in young, adult and elderly of advanced stage colorectal cancer patients |
Budhi I, Bagus M, Ayu S, et al. |
|
| 40. |
LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042 |
Herbst R, Lopes G, Kowalski D, et al. |
|
| 41. |
131P PD-1 and LAG-3 synergize to drive tumour-infiltration of T cytotoxic cells in NSCLC tumours |
Juncker-Jensen A, Nagy M, Kuo J, et al. |
|
| 42. |
95O The immunoglobulin superfamily receptome defines cancer-relevant networks associated with response to immunotherapy |
Martinez-Martin N, Verschueren E, Husain B. |
|
| 43. |
129O Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+ T cells (PD1tR) driven by tumour CD155 |
de Oliveira A, Madore J, O’donnell J, et al. |
|
| 44. |
44P Evaluation of immune response in young patients with sarcoma treated by dendritic cell-based immunotherapy |
Fedorova L, Dubska L, Selingerova I, et al. |
|
| 45. |
138P Prognostic implications of residual disease tumour-infiltrating lymphocytes in gastric cancer patients after neoadjuvant chemotherapy |
Xing X, Jia S, Feng Y, et al. |
|
| 46. |
146P The dynamics between neo-adjuvant treatment and immune responses in human breast cancer |
Thomas N, Garaud S, De Wind A, et al. |
|
| 47. |
63P Influence of nivolumab on epidemiology of infectious complications in patients with relapse or refractory Hodgkin’s lymphoma |
Rogacheva Y, Popova M, Lepik K, et al. |
|
| 48. |
158P Role of iron metabolism in the immunosuppression mediated by myeloid cells in glioblastoma patients |
Magri S, Pinton L, Masetto E, et al. |
|
| 49. |
79P Nivolumab treatment beyond progression disease in advanced non-small cell lung cancer |
Enomoto T, Tamiya A, Matsumoto K, et al. |
|
| 50. |
111P Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors |
Moerk S, Donia M, Kringelum J, et al. |
|
| 51. |
62P Safety and efficacy of allogeneic stem cell transplantation after nivolumab therapy for patients with relapsed/refractory classical Hodgkin lymphoma |
Beynarovich A, Lepik K, Mikhailova N, et al. |
|
| 52. |
128TiP VCN-01 plus durvalumab in subjects with recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC): Phase I clinical trial |
Jove M, Braña I, Taberna M, et al. |
|
| 53. |
10P Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC |
Mazzaschi G, Minari R, Ferri V, et al. |
|
| 54. |
112P Identification of a novel promiscuous anti-NY-ESO-1 immunogenic CD4+ peptide containing a CD8+ T-cell epitope highly present in metastatic gastric cancer responding to combined radiotherapy/anti-PD-1 immunotherapy |
Merhi M, Raza A, Inchakalody V, et al. |
|
| 55. |
61P Immunotherapy in patients with relapsed/refractory HIV-related lymphomas |
Popova M, Rogacheva Y, Tsygankov I, et al. |
|
| 56. |
87P Clinical outcomes of metastasic melanoma patients treated with ipilimumab and nivolumab: A single institution experience |
Oberoi H, Vila C, Rodriguez A, et al. |
|
| 57. |
150P Intratumoural MDSC recruitment by chemotherapeutic agent, 5-FU offsets the anti-tumor activity of immune-checkpoint inhibitor in HCC |
Kwong T, Wong C, Zhou J, et al. |
|
| 58. |
1O Harmonization and standardization of panel-based tumour mutational burden (TMB) measurement: Real-world results and recommendations of the QuIP study |
Stenzinger A, Endris V, Budczies J, et al. |
|
| 59. |
120P Combination of triptorelin with nivolumab in ICI resistant advanced melanoma |
Robert C, Lejeune F, Lebbé C, et al. |
|
| 60. |
94O Safety and antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors: Ovarian cancer cohort data |
Gao B, Goh J, Markman B, et al. |
|
| 61. |
76P Real-world data analysis of PD-L1 expression and overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) |
Staib J, Sudarsanam S, Byfield S, et al. |
|
| 62. |
18P The role of circulating neutrophils in the regulation of neoangiogenesis in ovarian cancer |
Abakumova T, Antoneeva I, Gening S, et al. |
|
| 63. |
119P Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimab in patients with advanced melanoma |
Tjulandin S, Fedyanin M, Demidov L, et al. |
|
| 64. |
145P Immune-competent 3D InSightTM tumour models as novel platform to assess combinatorial biologics therapy |
Chiovaro F, Buschmann N, Strebel S, et al. |
|
| 65. |
23P Immunological signature meta-analysis across lung cancer cohorts within the NanoString Clinical Transcriptional Atlas Group (CTAG) associated with patient outcome and history |
Radosevic-Robin N, Reeves J, Leroy K, et al. |
|
| 66. |
156P T-cell and B-cell intratumoural interactions affect the progression of oropharyngeal squamous cell carcinoma |
Hladikova K, Koucky V, Boucek J, et al. |
|
| 67. |
118P The role of asunercept as a selective CD95L inhibitor in cutaneous melanoma: Rationale and results from an enhanced TiRP model |
Krendyukov A, Kneisel N, Zhu J, et al. |
|
| 68. |
109P Phase I clinical study for validation of fimaporfin-based photochemical internalisation: A novel technology for enhancing cellular immune responses important for therapeutic effect of peptide-and protein-based vaccines |
Selbo P, Janetzki S, Welters M, et al. |
|
| 69. |
164P Combined detection of CD137 and type 1 functions improves identification and characterization of the activated T lymphocyte repertoire |
Draghi A, Gokuldass A, Chamberlain C, et al. |
|
| 70. |
70P Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors |
de Miguel P, Gallego J, García I, et al. |
|
| 71. |
74P Cost of adverse events (AEs) with second-line (2L) immuno-oncology agents (IO) and chemotherapy (CHEMO) in advanced non-small cell lung cancer (aNSCLC) in the real-world |
Wang C, Gupte-Singh K, Belli A, et al. |
|
| 72. |
93O First results of phase I/II studies evaluating viral vector-based heterologous prime/boost immunotherapy against predicted HLA class I neoantigens demonstrate CD8 T cell responses in patients with advanced cancers |
Johnson M, Spira A, Carbone D, et al. |
|
| 73. |
133P Tumour immune infiltrate characterization in luminal breast cancer in three distinct age categories and its correlation with frailty |
Berben L, Wildiers H, Kenis C, et al. |
|
| 74. |
34P Development of LAG-3 nanobodies as potent cancer imaging tracers |
Lecocq Q, Awad R, Zeven K, et al. |
|
| 75. |
98P Results from a phase I study of MK-1308 (anti–CTLA-4) plus pembrolizumab in previously treated advanced small cell lung cancer |
Cho B, Yoh K, Bar J, et al. |
|
| 76. |
43P Enhancing the therapeutic effect of dendritic cell therapy by oncolytic adenovirus 3 encoding CD40-ligand |
Zafar S, Quixabeira D, Hemminki O, et al. |
|
| 77. |
148P NKG2E comprises an immunogenic peptide, derived from an alu-retrotransposon: An attractive novel target for immunotherapeutic approaches |
Papamichos S. |
|
| 78. |
86P A novel ImmunoScore, based on clinical and blood biomarkers, as prognostic model for immunotherapy in NSCLC |
Viscardi G, Sparano F, Di Liello R, et al. |
|
| 79. |
97P Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti–PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC) |
Rischin D, Khushalani N, Schmults C, et al. |
|
| 80. |
17P Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients |
Blanc-Durand F, Auclin E, Planchard D, et al. |
|
| 81. |
90TiP FRAIL-IMMUNE: A multicenter, prospective, single arm phase II of the combination of durvalumab with carboplatin and paclitaxel as first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible to standard chemotherapy (GORTEC 2018-03) |
Fayette J. |
|
| 82. |
144P Loss of BAP-1 influences the activation of p52 and RelB proteins in the Inflammatory microenvironment of uveal melanoma |
Singh M, Kashyap S, Singh L, et al. |
|
| 83. |
2O Biomarkers of immune switch induced by a novel anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in MATINS trial patients with advanced solid tumours |
Hollmén M, Virtakoivu R, Jaakkola P, et al. |
|
| 84. |
155P Interleukin 17F and vasculogenic mimicry: Potential therapeutic targets in oral tongue cancer? |
Almahmoudi R. |
|
| 85. |
88P A study on analysis of clinical efficacy factor and exploring prognostic factors for reimbursement policy after immunotherapy being introduced in South Korea |
YI J. |
|
| 86. |
127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours |
Reck M, Cappuzzo F, Rodriguez-Abreu D, et al. |
|
| 87. |
28P RNA-seq based transcriptome profiling provides important insights into progression of gastric cancer |
Verma R. |
|
| 88. |
108P Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances Th1 cytokine production |
Gavin M, Gragerov A, Espling E, et al. |
|
| 89. |
80P Nintedanib (N) + docetaxel (D) after immunotherapy in adenocarcinoma non-small cell lung cancer (NSCLC): First results from the non-interventional LUME-BioNIS study |
Reck M, Syrigos K, Miliauskas S, et al. |
|
| 90. |
69P Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt) |
Hernando-Calvo A, Mirallas O, Marmolejo D, et al. |
|
| 91. |
40P Treatment of refractory recurrent gastrointestinal stromal tumors with adoptive cellular immunotherapy (TILs) and personalized vaccine |
Tavartkiladze A, Khutsishvili R, Revazishvili P, et al. |
|
| 92. |
92O Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817 |
Barlesi F, Audigier-Valette C, Felip E, et al. |
|
| 93. |
169P Impact of open-label design on patient-reported outcomes (PROs) data in randomized clinical trials of immuno-oncology (IO) agents in patients with advanced or metastatic cancer: A 10-year systematic literature review (SLR) |
Anota A, Pozet A, Lefevre C, et al. |
|
| 94. |
33P Tumour mutational burden ring trial: Evaluation of targeted next-generation sequencing platforms for implementation in clinical practice |
Lambin S, Lambrechts D, De Rop C, et al. |
|
| 95. |
27P Single-nucleotide polymorphism variation (SNV): Possible candidates as predictive biomarkers to response and progression free survival (PFS) in cutaneous malignant melanoma (CMM) patients treated with immune checkpoint inhibitors (ICI) |
Svedman F, Yang M, Tuominen R, et al. |
|
| 96. |
85P Impact of digital patient monitoring (DPM) on quality of clinical care of cancer immunotherapy (CIT)-treated patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC) |
Schmalz O, Jacob C, Ammann J, et al. |
|
| 97. |
11P PD-L1 profiling of circulating tumour cells is a viable companion diagnostic for checkpoint inhibitor therapy in lung cancer |
Patil R, Limaye S, Akolkar D, et al. |
|
| 98. |
143P Association of PTPRT mutation with survival of immune checkpoint inhibitor in patients with cancer |
Li A, Lin D, Yu Y, et al. |
|
| 99. |
104P A novel immunological role of hydrogen sulphide in shaping natural killer cells cytoxicity in breast cancer patients |
Youness R, Abdelmotaal A, Gad M. |
|
| 100. |
16P Neutrophil-lymphocyte ratio as a prognostic marker in a resource constraint setting for metastatic malignancies treated with immune checkpoint inhibitors |
Murthy N, Rauthan A, Patil P, et al. |
|
| 101. |
122P Local thermal ablation reboots the response in advanced hepatocellular carcinoma with stable or atypical progressive diseases during anti-PD-1 therapy |
Zhao M, Huang J, Lyu N, et al. |
|
| 102. |
154P ER stress of cancer cell SCC25 induces LOX-1-expressed immunosuppressive neutrophils |
Wu C, Wang C, Tai T, et al. |
|
| 103. |
168P Analysis of endpoints used for FDA approvals of checkpoint inhibitors |
Mendoza L. |
|
| 104. |
68P Dynamic changes in neutrophil-to-lymphocyte ratio of head and neck cancer patients receiving nivolumab in a real-world setting |
Cabezas-Camarero S, Abad D, de la Varga L, et al. |
|
| 105. |
26P Transforming growth factor-β makes the key characteristics of the proteome CD133- differentiated cells closer to CD133+ cancer stem cells of glioblastoma |
Zaitsev S, Shevchenko V, Arnotskaya N, et al. |
|
| 106. |
42P GMP-compliant human monocyte-derived dendritic cells for cancer vaccination generated by using the Quantum® hollow fiber bioreactor system |
Uslu U, Erdmann M, Wiesinger M, et al. |
|
| 107. |
103P Combinatorial unique photothermal tumour immunotherapy against targeted triple negative breast cancer therapy of dual modal nanoplatform |
Raju V, Yasothamani V, Shyamsivappan S, et al. |
|
| 108. |
107P Increasing responses to T-cell therapies in solid tumours by the use of an engineered adenovirus coding for TNFa and IL-2 |
Cervera-Carrascon V, Havunen R, Santos J, et al. |
|
| 109. |
167P Efficacy of cetuximab based chemotherapy after immunotherapy treatments (IT) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) |
Hernando-Calvo A, Mirallas O, Marmolejo D, et al. |
|
| 110. |
173TiP PECan study, imaging PD-L1 in cancer: A tool for measuring response to immunotherapy? |
Hughes D, Chand G, Josephs D, et al. |
|
| 111. |
121P Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: Final data |
Ridolfi L, Bulgarelli J, Petracci E, et al. |
|
| 112. |
32P A comprehensive tumour immunogenomics platform for precision immunotherapy: Enabling simultaneous characterization of tumours and the TME from a single FFPE sample |
Power R, Bartha G, Harris J, et al. |
|
| 113. |
25P Analysis of NGS-based blood immune cell RNA signatures for colorectal cancer detection |
Morgenthaler S, Lindsay H, Ciarloni L, et al. |
|
| 114. |
84P Survival outcomes in stage IV small-cell lung cancer (IV-SCLC): Analysis from SEER database |
de Castro Carpeño J, Dols M, Gomez M, et al. |
|
| 115. |
136P Profiling the tumour immune microenvironment in pleomorphic dermal sarcomas suggests its potential effectiveness for immunotherapy |
Noh K, Klein S, Mauch C, et al. |
|
| 116. |
15P Immune escape in acute myeloid leukemia |
Kuzelova K, Brodská B, Otevřelová P, et al. |
|
| 117. |
9P Overall assessment of tumour-infiltrating lymphocytes in early-stage nasopharyngeal carcinoma |
Almangush A. |
|
| 118. |
142P Association of MUC16 mutation with survival of immune checkpoint inhibitor in patients with cancer |
Ou Q, Lin D, Yu Y, et al. |
|
| 119. |
59P Checkpoint inhibitors and conventional therapy for central nervous system lymphoma |
Shmidt D, Gavrilenko A, Polushin A, et al. |
|
| 120. |
126TiP A phase I study of NBTXR3 activated by radiotherapy for patients with advanced cancers treated with an anti-PD-1 therapy |
Shen C, Jameson K, Weiss J, et al. |
|
| 121. |
24P Multiple KRAS mutations detected by cancer related DNA in patients with resected pancreas adenocarcinoma during treatment with TG01/GM-CSF and gemcitabine (CT TG01-01) |
Palmer D, Møller A, Greenhalf B, et al. |
|
| 122. |
153P Immune-microbial crosstalk in oral epithelium: A potential role in oral carcinogenesis? |
Salem A, Eklund K. |
|
| 123. |
101P Results of the NLG2105 phase I trial using the IDO pathway inhibitor indoximod, in combination with radiation and chemotherapy, for children with newly diagnosed DIPG |
Johnson T, Aguilera D, Al-Basheer A, et al. |
|
| 124. |
67P Real-world outcomes for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab |
Singh P, You M, Lubinga S, et al. |
|
| 125. |
58P Risk factors for immune related adverse events: A retrospective study |
Parmanande A, Barreira J, Spencer A, et al. |
|
| 126. |
172P miR-486-5p counteracts the shedding of MICA/B and CD155 immune-ligands in TNBC patients |
Elkhouly A, Youness R, Gad M. |
|
| 127. |
8P The prognostic value of tumour-infiltrating lymphocytes (TILs) in pancreatic cancer: A systematic review and meta-analysis |
Orhan A, Vogelsang R, Andersen M, et al. |
|
| 128. |
31P Development of a biomarker-based calculator to predict the probability to achieve a pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer |
Marandino L, Bandini M, Madison R, et al. |
|
| 129. |
165P Pre-therapeutic evaluation of patient-specific responses to immune-checkpoint inhibition in colorectal cancer |
Sturmheit T, Konczalla L, Temovski T, et al. |
|
| 130. |
83P Analysis of predictive factors in non-small cell lung cancer patients treated with nivolumab |
Azuma K, Tamiya A, Adachi Y, et al. |
|
| 131. |
75P Immune-related toxicities in NSCLC: Real-world experience from a tertiary cancer center |
d'Arienzo P, Olsson-Brown A, Sallam M, et al. |
|
| 132. |
141P Identifying mechanisms of macrophage-mediated metastasis and treatment resistance in pancreatic cancer |
Wu T. |
|
| 133. |
57P Immune-related adverse events: The experience of a community hospital |
de Almeida S, Honório M, Guerra N, et al. |
|
| 134. |
125P Response assessment of metastatic uveal melanoma treated with rose bengal disodium |
Carter B, Murthy R, Balmes G, et al. |
|
| 135. |
149P Revamping the ovarian tumour microenvironment with an oncolytic adenovirus yields enhanced tumour-infiltrating lymphocyte anti-tumour activity |
Santos J, Heiniö C, Cervera-Carrascon V, et al. |
|
| 136. |
66P Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455) |
Grohe C, Gleiber W, Krüger S, et al. |
|
| 137. |
134P Comprehensive assessment of anti-tumour PDL1 blockade effect in a sarcoma mouse model |
Nafia I, Chaibi A, Bortolotto D, et al. |
|
| 138. |
14P Anti-PDL1/IL-15 fusion protein increases rare effector cells in cynomolgus monkeys and mice |
Martomo S, Lu D, Polonskaya Z, et al. |
|
| 139. |
22P Early changes in plasma cell-free DNA (cfDNA) as a predictive biomarker of immune checkpoint inhibitors (ICIs) efficacy |
Garcia I, Moreno A, Arenillas C, et al. |
|
| 140. |
82P Real-world survival with first-line (1L) chemotherapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC) |
Waterhouse D, Betts K, Zhao J, et al. |
|
| 141. |
117P Immune checkpoint inhibitors (ICI) in combination with chemotherapy as first-line (1L) treatment for non-small cell lung cancer (NSCLC): A pair-wise meta-analysis (MA) |
Afonso-Afonso F, Gancedo M, Manrique M, et al. |
|
| 142. |
171P Treatment (tx) patterns of patients with advanced renal cell carcinoma (aRCC) receiving first-line (1L) tx: Results from a cross-sectional real-world study |
Zanotti G, Kim R, Krulewicz S, et al. |
|
| 143. |
99P A platform for extracellular interactome discovery identifies novel functional binding partners for the immune receptors B7-H3/CD276 and PVR/CD155 |
Husain B, Martinez-Martin N. |
|
| 144. |
106P A single dose of local IL-12 promotes anti-tumor effect of anti-EGFRvIII-CAR-T cells in a syngeneic murine model of glioblastoma |
Liuzzi A, Agliardi G, Becher B, et al. |
|
| 145. |
37P Chemokine receptor CCR2b expressing anti-Tn-MUC1 CAR-T cells enhanced anti-breast cancer activity |
Lin Y, Yin H, An H, et al. |
|
| 146. |
30P Transcriptomic landscape of tumour cells undergoing T-cell attack |
Gokuldass A, Schina A, Lauss M, et al. |
|
| 147. |
21P Prognostic biomarkers in lung cancer patients treated with immunotherapy |
Ferreira S, Esteves S, Almodovar M. |
|
| 148. |
140P B-cell clusters in the stroma at invasive tumour margin provide prognostic value in early-stage oral-tongue cancer patients: The discovery and validation study |
Phanthunane C, Wijers R, De Herdt M, et al. |
|
| 149. |
55P Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study |
Nigro O, Cortellini A, Giusti R, et al. |
|
| 150. |
41P Pharmacotherapy preceding monocyte harvest interferes with the potency of monocyte-derived dendritic cell anticancer vaccine |
Hlavackova E, Pilatova K, Fedorova L, et al. |
|
| 151. |
73P Real-world experience of immune-mediated hepatitis in Danish lung cancer patient using PD1 inhibitors |
Lauritsen L, Persson G, Poehl M, et al. |
|
| 152. |
65P Determination of anti-pancreatic islet cell antibodies for the prevention of type 1 diabetes mellitus as an immune-related adverse event secondary to treatment with immune checkpoint inhibitors |
Hernández A, Cornejo R, Pérez L, et al. |
|
| 153. |
5P Differential expression patterns of immune checkpoint markers in tumour-stromal microenvironment of primary and chemoreduced retinoblastoma |
Singh L, Singh M, Rizvi M, et al. |
|
| 154. |
13P MDSC (myeloid-derived suppressor cells) is an important immunosuppressing factor and functionally related with VEGF and IL-17 in patients with gastrointestinal cancer |
Shibata M, Nakajima T, Mimura K, et al. |
|
| 155. |
132P Correlation between tumour infiltration lymphocyte and PDL-1 expression in laryngeal cancer and its prognostic significance: A prospective, non-interventional trial |
Ismail M, Wakiel H, Ghany D, et al. |
|
| 156. |
29P Expression profiles of serum long non-coding RNA in ovarian cancer patients receiving platinum-containing chemotherapy |
Gening S, Dolgova D, Abakumova T, et al. |
|
| 157. |
72P Evaluation of the correlation between diverticulosis and the onset of diarrhea in patients with lung cancer treated with immune checkpoint inhibitors |
Negrini G, Ghilardi L, Bonomi L, et al. |
|
| 158. |
152P Replicative potency of oncolytic VSV-GP differentially shapes the immune signature in three distinct syngeneic tumour models |
Wollmann G, Spiesschaert B, Das K, et al. |
|
| 159. |
115P Therapeutic efficacy of combining the tumour checkpoint controller BAL101553 (lisavanbulin) and immunomodulation in two mouse glioma models with different immunological status |
Genoud V, Marinari E, Bes V, et al. |
|
| 160. |
170P Anti-α gal antibodies in the context of blood group and stool and tumour-adjacent microbiome in colorectal cancer patients |
Selingerova I, Budinska E, Zwinsova B, et al. |
|
| 161. |
3O A pre-existing inflammatory immune microenvironment predicts the clinical and immunological response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 peptide vaccination |
Abdulrahman Z, de Miranda N, van Poelgeest M, et al. |
|
| 162. |
139P Multiplex IHC panel development for adenosine pathway markers and TIL in human cancer specimens |
Pabois A, Bodo V, Boisson A, et al. |
|
| 163. |
36P First CAR-T cell immunotherapy against HLA-G: Targeting a unique ICP and TAA |
Loustau M. |
|
| 164. |
81P Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) progressing after immune checkpoint inhibitors - AVATAX , a retrospective multicentric study: Preliminary data |
Valery S, Chouaid C, Rousseau-Bussac G, et al. |
|
| 165. |
19P The prognostic nutritional index and neutrophil-to-lymphocyte ratio as prognostic factors in advanced non-small cell lung cancer patients treated with immunotherapy |
Cipriano É, Magalhães H, Estevinho F, et al. |
|
| 166. |
105P Discovery of bioactive small molecule inhibitors of human PD1-PDL1 interaction |
Patil S, Diflumeri J, Fattakhova E. |
|
| 167. |
53P Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience |
Samanci N, Oruc K, Bedir S, et al. |
|
| 168. |
124P A phase I study of percutaneous oncolytic rose bengal disodium for metastatic uveal melanoma patients with hepatic metastases: A single-center cohort summary |
Patel S, Carter B, Balmes G, et al. |
|
| 169. |
114P Targeting the EGF-receptor and CD38 in solid and haematological malignancies with nanobody-based heavy chain antibodies and AAV vectors |
Baum N. |
|
| 170. |
64P Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter? |
Lee J, Ng K, Wong L, et al. |
|
| 171. |
71P Correlation between toxicities and outcomes during treatment with immune checkpoint inhibitors in non-small cell lung cancer patients |
de Miguel P, Díez S, García I, et al. |
|
| 172. |
50P Predicting onset and continuity of patient-reported symptoms in cancer patients undergoing immune checkpoint inhibitor (ICI) therapies using machine learning |
Livanainen S, Ekström J, Virtanen H, et al. |
|
